Benzinga
Published May 02, 2024 16:00
Updated May 02, 2024 17:11
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing Regeneron Pharmaceuticals (NASDAQ:REGN) alongside its primary competitors in the Biotechnology industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company's performance within the industry.
Regeneron Pharmaceuticals Background Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Regeneron Pharmaceuticals Inc | 25.97 | 3.83 | 7.83 | 4.56% | $1.28 | $2.92 | 0.58% |
Amgen Inc | 22.21 | 23.87 | 5.29 | 11.05% | $3.05 | $5.08 | 19.84% |
Vertex Pharmaceuticals Inc | 28.95 | 5.91 | 10.62 | 5.68% | $1.22 | $2.15 | 9.34% |
Biogen Inc | 27.02 | 2.07 | 3.26 | 2.62% | $0.68 | $1.75 | -7.0% |
BioNTech SE | 21.92 | 1 | 5.33 | 2.28% | $0.46 | $1.3 | -65.43% |
Genmab A/S | 30.28 | 4.09 | 8 | 2.04% | $0.93 | $4.55 | -8.94% |
Biomarin Pharmaceutical Inc | 78.61 | 3.12 | 6.50 | 1.77% | $0.14 | $0.52 | 8.79% |
Neurocrine Biosciences Inc | 38.91 | 6.04 | 7.41 | 6.98% | $0.2 | $0.51 | 25.05% |
Incyte Corp | 16.04 | 2.20 | 3.18 | 3.2% | $0.26 | $0.82 | 8.93% |
United Therapeutics Corp | 12.07 | 2.12 | 5.08 | 3.71% | $0.32 | $0.54 | 25.07% |
Roivant Sciences Ltd | 2.13 | 1.48 | 73.11 | 144.81% | $5.11 | $0.03 | 117.8% |
Average | 27.81 | 5.19 | 12.78 | 18.41% | $1.24 | $1.73 | 13.34% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } After examining Regeneron Pharmaceuticals, the following trends can be inferred:
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When examining Regeneron Pharmaceuticals in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.